GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.86 Million USD | 0.0% |
| 2022 | 1.26 Million USD | -86.09% |
| 2021 | 9.09 Million USD | 3317.13% |
| 2020 | 266.06 Thousand USD | -15.84% |
| 2019 | 316.14 Thousand USD | -10.12% |
| 2018 | 351.73 Thousand USD | -23.69% |
| 2017 | 460.9 Thousand USD | 196.44% |
| 2016 | 155.48 Thousand USD | -73.58% |
| 2015 | 588.42 Thousand USD | 10.4% |
| 2014 | 532.98 Thousand USD | -13.5% |
| 2013 | 616.13 Thousand USD | -34.8% |
| 2012 | 944.96 Thousand USD | 1646.54% |
| 2011 | 54.1 Thousand USD | 2503.71% |
| 2010 | 2078.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 167.58 Thousand USD | 7.51% |
| 2024 Q3 | 193.35 Thousand USD | 15.38% |
| 2024 Q1 | 155.87 Thousand USD | -45.84% |
| 2023 Q3 | 1.27 Million USD | 800.53% |
| 2023 Q2 | 142.05 Thousand USD | -8.49% |
| 2023 Q1 | 155.24 Thousand USD | -48.23% |
| 2023 FY | 1.26 Million USD | 0.0% |
| 2023 Q4 | 287.78 Thousand USD | -77.5% |
| 2022 Q1 | 166.29 Thousand USD | -95.93% |
| 2022 Q2 | 662.31 Thousand USD | 298.28% |
| 2022 FY | 1.26 Million USD | -86.09% |
| 2022 Q4 | 299.84 Thousand USD | 119.48% |
| 2022 Q3 | 136.61 Thousand USD | -79.37% |
| 2021 Q4 | 4.08 Million USD | -8.77% |
| 2021 Q2 | 467.99 Thousand USD | 675.42% |
| 2021 Q3 | 4.47 Million USD | 856.88% |
| 2021 FY | 9.09 Million USD | 3317.13% |
| 2021 Q1 | 60.35 Thousand USD | -34.27% |
| 2020 FY | 266.06 Thousand USD | -15.84% |
| 2020 Q1 | 74.29 Thousand USD | 20.11% |
| 2020 Q2 | 51.38 Thousand USD | -30.83% |
| 2020 Q4 | 91.81 Thousand USD | 89.07% |
| 2020 Q3 | 48.56 Thousand USD | -5.5% |
| 2019 Q2 | 70.78 Thousand USD | -45.39% |
| 2019 Q3 | 53.87 Thousand USD | -23.89% |
| 2019 Q4 | 61.85 Thousand USD | 14.82% |
| 2019 Q1 | 129.62 Thousand USD | 16.23% |
| 2019 FY | 316.14 Thousand USD | -10.12% |
| 2018 Q3 | 69.79 Thousand USD | 67.27% |
| 2018 Q1 | 128.69 Thousand USD | 414.39% |
| 2018 FY | 351.73 Thousand USD | -23.69% |
| 2018 Q4 | 111.52 Thousand USD | 59.79% |
| 2018 Q2 | 41.72 Thousand USD | -67.58% |
| 2017 FY | 460.9 Thousand USD | 196.44% |
| 2017 Q4 | 25.01 Thousand USD | -68.41% |
| 2017 Q3 | 79.18 Thousand USD | -33.93% |
| 2017 Q2 | 119.86 Thousand USD | -49.39% |
| 2017 Q1 | 236.83 Thousand USD | 0.0% |
| 2016 Q3 | 25.29 Thousand USD | -74.06% |
| 2016 FY | 155.48 Thousand USD | -73.58% |
| 2016 Q2 | 97.51 Thousand USD | -18.03% |
| 2016 Q1 | 118.97 Thousand USD | -43.85% |
| 2015 Q2 | 147.75 Thousand USD | 32.35% |
| 2015 FY | 588.42 Thousand USD | 10.4% |
| 2015 Q1 | 111.64 Thousand USD | 111.23% |
| 2015 Q4 | 211.86 Thousand USD | 80.84% |
| 2015 Q3 | 117.15 Thousand USD | -20.71% |
| 2014 Q4 | 52.85 Thousand USD | -69.39% |
| 2014 Q2 | 119.15 Thousand USD | -36.73% |
| 2014 FY | 532.98 Thousand USD | -13.5% |
| 2014 Q3 | 172.65 Thousand USD | 44.9% |
| 2014 Q1 | 188.31 Thousand USD | -27.59% |
| 2013 Q1 | 82.78 Thousand USD | 61.94% |
| 2013 Q4 | 260.05 Thousand USD | 108.77% |
| 2013 FY | 616.13 Thousand USD | -34.8% |
| 2013 Q3 | 124.56 Thousand USD | -16.24% |
| 2013 Q2 | 148.72 Thousand USD | 79.65% |
| 2012 Q4 | 51.12 Thousand USD | -92.92% |
| 2012 Q3 | 722.21 Thousand USD | 602.1% |
| 2012 Q2 | 102.86 Thousand USD | 49.59% |
| 2012 Q1 | 68.76 Thousand USD | 112.07% |
| 2012 FY | 944.96 Thousand USD | 1646.54% |
| 2011 Q2 | 2100.00 USD | -2.33% |
| 2011 Q1 | 2150.00 USD | 0.0% |
| 2011 Q3 | 17.42 Thousand USD | 729.95% |
| 2011 Q4 | 32.42 Thousand USD | 86.04% |
| 2011 FY | 54.1 Thousand USD | 2503.71% |
| 2010 FY | 2078.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -39.608% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 63.024% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 93.691% |
| Nascent Biotech, Inc. | 2.22 Million USD | 16.391% |
| Rebus Holdings, Inc. | 664 Thousand USD | -180.779% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 94.996% |
| Qrons Inc. | 643.67 Thousand USD | -189.644% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -378.576% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.754% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -348.728% |
| Skye Bioscience, Inc. | 13.54 Million USD | 86.238% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.852% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 62.09% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -612.337% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.822% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 36.069% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -24.134% |
| Mesoblast Limited | 5.9 Million USD | 68.411% |
| Marizyme, Inc. | 19.23 Million USD | 90.31% |
| Genus plc | 147.7 Million USD | 98.738% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 78.764% |
| Pharming Group N.V. | 225.49 Million USD | 99.173% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 8.998% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -38.972% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 77.643% |
| ContraFect Corporation | 56.88 Million USD | 96.723% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 57.711% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -26.077% |
| IMV Inc. | 37.7 Million USD | 95.056% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 33.185% |
| MultiCell Technologies, Inc. | 567.42 USD | -328469.666% |
| ONE Bio Corp. | 6.44 Million USD | 71.068% |
| Accustem Sciences Inc. | 3.74 Million USD | 50.236% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.831% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -250.471% |
| Q BioMed Inc. | 3.43 Million USD | 45.75% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 92.457% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 29.045% |
| Biomind Labs Inc. | 994.18 Thousand USD | -87.528% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.123% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -5.949% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 72.248% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 7557.48% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 88.355% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1.595% |
| GB Sciences, Inc. | 1.42 Million USD | -31.247% |
| Alpha Cognition Inc. | 9.7 Million USD | 80.791% |
| HST Global, Inc. | 140.9 Thousand USD | -1223.121% |
| CSL Limited | 3.44 Billion USD | 99.946% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -65.735% |
| Halberd Corporation | 74.84 Thousand USD | -2391.075% |
| Enzolytics Inc. | 2.17 Million USD | 14.459% |
| Agentix Corp. | 1.37 Million USD | -35.911% |
| Resverlogix Corp. | 12.71 Million USD | 85.334% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 48.931% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.878% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -78.58% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 22.477% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -18.046% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 45.246% |
| AVAX Technologies, Inc. | 7.31 Million USD | 74.497% |
| Zenith Capital Corp. | 8.94 Million USD | 79.153% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.774% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -10601.854% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 24.068% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -987.039% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 2.943% |
| Kadimastem Ltd | 2.41 Million USD | 22.644% |
| Helix BioMedix, Inc. | 1.97 Million USD | 5.46% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 82.844% |
| BioStem Technologies, Inc. | 22.97 Million USD | 91.885% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -927.286% |
| LadRx Corporation | 3.81 Million USD | 51.089% |
| Cell Source, Inc. | 4.32 Million USD | 56.897% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -101.879% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -101.879% |
| NovAccess Global Inc. | 2.46 Million USD | 24.42% |
| Affymax, Inc. | 39.38 Million USD | 95.266% |
| Itoco Inc. | 919.14 Thousand USD | -102.838% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 56.013% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -66.61% |
| Mobile Lads Corp. | 554.54 Thousand USD | -236.198% |
| CytoDyn Inc. | 18.05 Million USD | 89.676% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -7307.406% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -747.141% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -31.313% |
| SYBLEU INC | 160.87 Thousand USD | -1058.886% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -2.645% |
| International Stem Cell Corporation | 5.27 Million USD | 64.63% |
| Bioxytran, Inc. | 3.82 Million USD | 51.196% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -3441.602% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -9064.676% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 94.859% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -15.227% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -153.368% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 40.072% |
| Neutra Corp. | 243.82 Thousand USD | -664.647% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 89.32% |
| PureTech Health plc | 144.59 Million USD | 98.711% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 90.901% |
| IXICO plc | 4.7 Million USD | 60.392% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 78.807% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.417% |
| CSL Limited | 3.89 Billion USD | 99.952% |
| Cellectis S.A. | 97.32 Million USD | 98.084% |